

SomaScan[®] Assay

A proteomics platform driving pioneering discoveries

Discover *new disease biomarkers* through high-throughput protein profiling

7,000	~5%	10 log	>500	>550,000
proteins analyzed in each 55 µL sample	median coefficient of variation for plasma	dynamic range from fM to µM	publications to date	samples run to date

Key disease areas

Cardiovascular disease

Circulating proteins are powerful indicators of cardiovascular disease. More than 55 cardiovascular disease publications feature data from the SomaScan Assay.

Diabetes

Models built from data from the SomaScan Assay have been used to predict progression from prediabetes to diabetes.

Oncology & Immunotherapy

Identify and characterize cancers and predict response to immunotherapy by measuring circulating proteins.

Nonalcoholic fatty liver disease

The SomaScan Assay can be used to detect biomarkers associated with nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.

Rare disease

The SomaScan Assay has been used in biomarker discovery and pathway analysis to aid in the diagnosis and development of effective treatments for rare diseases.

Neurology

With the ability to profile 7,000 proteins simultaneously, the SomaScan Assay is well-suited to measuring low and highly abundant proteins in a small amount of blood or cerebrospinal fluid.

Custom and disease-specific panels are also available for a more targeted approach to your protein profiling.


Identify biomarkers and biomarker pathways for:

Pharmaceutical R&D

- Target identification
- Target validation
- Mechanism of action
- Pharmacokinetics/pharmacodynamics
- Enrichment of clinical trials
- Stratification of clinical trials

Academic R&D

- Disease biology modeling
- Disease sub-phenotyping
- Physiology investigation
- Pathway regulation investigation
- Rapid translation from bench to bedside
- Dovetailing with clinical care



SomaLogic's project managers provide additional support through the process.

Abbreviations: CAP, College of American Pathologists; CLIA, Clinical Laboratory Improvement Amendments.

SomaScan [Assay] is the state-ofart proteomic platform in multiplex, sensitivity and throughput."





Learn more about the SomaScan Assay somalogic.com/somascan-assay

SL00000280 Rev 4 2022-08

SomaScan Assay Brochure

SomaLogic® SomaScan® SOMAmer® and associated logos are trademarks of SomaLogic Operating Co., Inc. and any third-party trademarks used herein are the property of their respective owners. © 2022 SomaLogic Operating Co., Inc. I 2945 Wilderness PI, Boulder, CO 80301 I Ph 303 625 9000 I www.somalogic.com

